Larson Financial Group LLC Purchases 380 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Larson Financial Group LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 745.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 431 shares of the medical research company’s stock after acquiring an additional 380 shares during the period. Larson Financial Group LLC’s holdings in IQVIA were worth $102,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Advisors Asset Management Inc. raised its holdings in shares of IQVIA by 106.4% during the first quarter. Advisors Asset Management Inc. now owns 1,298 shares of the medical research company’s stock valued at $328,000 after purchasing an additional 669 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its holdings in shares of IQVIA by 13.9% during the first quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock valued at $902,000 after purchasing an additional 436 shares during the last quarter. Tidal Investments LLC raised its holdings in shares of IQVIA by 101.9% during the first quarter. Tidal Investments LLC now owns 7,637 shares of the medical research company’s stock valued at $1,931,000 after purchasing an additional 3,854 shares during the last quarter. Comerica Bank raised its holdings in shares of IQVIA by 2.9% during the first quarter. Comerica Bank now owns 41,440 shares of the medical research company’s stock valued at $10,480,000 after purchasing an additional 1,161 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of IQVIA during the first quarter valued at approximately $979,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on IQV shares. Truist Financial decreased their price objective on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday, November 4th. Evercore ISI decreased their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research report on Friday, November 1st. Finally, TD Cowen decreased their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Stock Performance

IQV opened at $201.43 on Friday. The stock has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 2.10 and a beta of 1.51. The company has a fifty day moving average of $219.50 and a 200 day moving average of $226.40. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.